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Dear Editor,
We report the management of a patient treated for POEMS syndrome who developed 
hypersensitivity reactions to both lenalidomide and pomalidomide.
A 70-year-old caucasian female patient known for hypertension without vascular complications 
and a history of autoimmune thyroiditis, as well as hyperprolactinemia secondary to 
metoclopramide use. In March 2015, she developed distal paraesthesia of the upper and lower 
limbs, which evolved into a distal paresis within two months, requiring the use of crutches. Six 
months later, she presented with night sweats and weight loss of eight kilograms. Additionally, 
cutaneous angioma and sclerodactylia appeared. Initially, nerve conduction studies were consistent 
with chronic demyelinating inflammatory polyradiculoneuritis (CIDP). However, treatment with 
intravenous polyclonal immunoglobulins proved unfavourable. Repeated immunosubtraction in 
serum and urine failed to reveal a monoclonal component, even 8 months after presentation, when 
a slight elevation of serum VEGF (343 pg/ml for a cut-off < 200 pg/ml) was observed.
Monoclonal IgA lambda gammopathy was finally detected by immunofixation analysis 14 months 
after the appearance of the first symptoms. Full blood count revealed a thrombocytosis of 
457x109/l as the only anomaly. At the same time, VEGF levels further increased to 917 pg/ml. A 
total body MRI demonstrated the presence of a splenomegaly (140 mm on the main axe) and a 
higher intensity of the bone marrow in comparison to the normal kidney parenchyma. Bone 
marrow tap revealed 8% of monoclonal plasma cells. An endocrinological workup excluded a 
clinically relevant endocrinopathy, aside from the pre-existing subclinical hypothyroidism. A 
cutaneous biopsy showed glomerular haemangioma.
According to the International Myeloma Working Group criteria, the diagnosis of POEMS 
syndrome was made (two mandatory criteria: polyneuropathy and monoclonal plasma cell 
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disorder; one major criterion: VEGF elevation; three minor criteria: splenomegaly, skin lesions 
(glomerular haemangioma and sclerodactily) and thrombocytosis) [1].
The patient was treated with lenalidomide (25 mg/d, d1-d21) and dexamethasone (40 mg/weekly) 
[2], together with fondaparinux (2.5mg/d). The patient was already on candesartan, 
hydrochlorothiazide and amitriptyline (introduced one year before to control neuropathic pain) for 
several years. Six days after starting lenalidomide, she developed a cutaneous grade 3 (according 
to CTCAE v4.03) maculo-papular rash with a moderate eosinophilia (0.97x109/l)without fever, 
renal or hepatic involvement. The lenalidomide treatment was interrupted and topical 
betamethasone was administered. One month later, after full resolution of the rash and of 
eosinophilia, an attempt to re-introduce a lower dose of lenalidomide (15 mg/d) associated with 
prednisone (20 mg/d) provoked the reoccurrence of the rash (grade 3) without eosinophilia. 
Lenalidomide treatment was interrupted, topical treatment with betamethasone was reintroduced 
and oral prednisone was slowly tapered. Two weeks later, the rash completely resolved. Because 
of the severity of the rash and its reoccurrence despite a concomitant treatment with oral 
prednisone, no desensitization for lenalidomide was attempted and the treatment was definitively 
interrupted.
Six weeks thereafter, lenalidomide was replaced by pomalidomide (4 mg/d) in combination with 
dexamethasone (40 mg/weekly). Two days after the treatment start, a grade 3 maculo-papular rash 
recurred, without eosinophilia. Delayed hypersensitivity to both lenalidomide and pomalidomide 
was diagnosed.
In analogy to a desensitization schedule for lenalidomide published in 2014 by Lee and colleagues 
[3], a desensitization for pomalidomide was started in October 2016 following a schedule 
summarized in table 1. The treatment with dexamethasone (40mg/weekly) was continued.
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The patient reached the target dose of 2 mg/d after 5 weeks without re-occurrence of adverse 
events.
The clinical as well as the biological evolution was favorable after three 28-days cycles associating 
pomalidomide and dexamethasone. The patient described a general improvement of her condition 
and a weight gain. She was able to walk short distances without assistance. The overall disability 
sum score (ODSS) [4] was 2 for the superior members and 3 for the inferiors members, as 
compared to 4 before the treatment. The monoclonal IgA lambda component disappeared in the 
blood immunofixation with a 50% decrease of the IgA level. VEGF normalised (88 pg/ml). 
However, ENMG analysis did not demonstrate any improvement of the demyelinizating signs.
A peripheral blood stem cell collection was performed after four cycles of 
pomalidomide/dexamethasone. A total of six cycles were given. The patient was then treated with 
high-dose melphalan (200 mg/m2) followed by an autologous stem cell transplantation 26 months 
after presentation.
The day 100 control was consistent with a complete response. One year after the autologous stem 
cell transplantation, the patient is still in ongoing response with a continuous neurological 
improvement.
Pomalidomide is an immunomodulatory agent approved for the treatment of adult patients with 
relapsed and refractory multiple myeloma (MM) [5].
The Food and Drug Administration (FDA) approved pomalidomide for single use in the United 
States in February 2013, and the European Medicines Agency (EMA) for use in combination with 
dexamethasone in patients with MM who have received at least two prior therapies including 
lenalidomide and bortezomib in August 2013. The molecule is structurally related to lenalidomide 
and thalidomide.
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In the multiple myeloma MM-003 study, cutaneous reactions were reported in less than 10% of 
patients treated with pomalidomide and low-dose dexamethasone [5]. Rash appeared to be less 
common with pomalidomide than with lenalidomide [6,7]. The structural similarity of both 
molecules suggests a potential for cross-sensitization. Because of this theoretical concern, patients 
having experienced hypersensitivity to immunomodulatory imid drugs were excluded from trials 
with pomalidomide [8]. Thus, clinical data regarding safety of pomalidomide in patients having 
experienced hypersensitivity reactions to lenalidomide are lacking. As proposed by an expert panel 
[9], pomalidomide should be used with caution in patients who developed a rash during prior 
treatment with lenalidomide or thalidomide. In patients developing mild-to-moderate 
maculopapular eruption or erythema, a treatment with low-dose prednisone and antihistamines 
may be adequate. In patients presenting with more severe reactions, the pomalidomide dose should 
be reduced or interrupted [9]. A desensitization procedure may be attempted in hypersensitive 
patients to whom no alternative treatment is available, if the reaction was not life threatening. One 
case report describes the rapid desensitization procedure to pomalidomide in a patient with 
relapsing myeloma and previous grade 3 rashes to both thalidomide and lenalidomide, in order to 
avoid potential cross-reactivity [10]. However, it is unknown whether the abovementioned patient 
would have reacted if exposed to standard-dose pomalidomide. In contrast, our patient presented 
with a grade 3 rash to both lenalidomide and pomalidomide. We used a slow desensitization 
protocol to avoid hospitalization and an individual pharmacy preparation (magistral preparation 
produced by the hospital pharmacy containing only a small amount of the active principle not 
industrially available, i.e. 0.00025 mg or 0.00125 mg). During the desensitization procedure, our 
patient was followed on a weekly basis with a clinical examination and laboratory screening. The 































































6rash did not re-occur and no other adverse events were observed, while the patient continued her 
treatment as planned.
Our case demonstrates that a slow desensitization procedure to pomalidomide may be performed 
safely in an outpatient setting after grade 3 rash to both pomalidomide and lenalidomide. 
Furthermore, to the best of our knowledge, this is the first description of the use of pomalidomide 
in POEMS.
In conclusion, pomalidomide may be considered an effective alternative to lenalidomide in patients 
with POEMS having experienced non-severe delayed skin reaction but carries the risk of recurrent 
rash. For patients with non-life-threatening delayed hypersensitivity to pomalidomide, a slow 
desensitization procedure may be attempted. Further studies are needed to assess the efficacy of 
pomalidomide in POEMS and its safety in case of hypersensitivity to other immunomodulatory 
imid drugs.
Consent
Signed informed consent from the patient was obtained for the off-label use of pomalidomide as 
well as for the publication of her case.
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Table 1. Desensitization schedule to pomalidomide (target dose of 2 mg/d)
Monday Tuesday Wednesday Thursday Friday Saturday Sunday
Week 1 1 mg
Week 2 1 mg 1 mg 1 mg
Week 3 1 mg 1 mg 1 mg 1 mg
Week 4 1 mg 1 mg 1 mg 2 mg 1 mg 2 mg 1 mg
Week 5 2 mg 2 mg 2 mg 2 mg 2 mg 2 mg 2 mg
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